Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Henry Schein (HSIC)

Henry Schein names Frederick Lowery CEO, effective March 2, 2026

Neutral Impact 4 of 5 leadership Written later

Henry Schein appointed Frederick M. Lowery, currently Executive Vice President and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, as chief executive officer effective March 2, 2026, and expanded its board from 14 to 15 members to seat him. Current CEO Stanley M. Bergman will remain CEO until Lowery starts, then become Chairman of the Board. The filing also amends the company's bylaws to remove the requirement that the board appoint a President.

Key points

  • Lowery's employment agreement sets a base salary of $1,250,000 and a target annual bonus of no less than 150% of base salary for 2026.
  • Lowery will receive a 2026 equity award with a target grant date fair value of $10,000,000, plus a $2,500,000 sign-on equity award vesting over three years.
  • Bergman continues as CEO until Lowery begins work, then becomes Chairman of the Board.
  • The board amended the bylaws effective January 10, 2026, to allow a CEO who is not also President or Chairman.

The filing

CompanyHenry Schein (HSIC)
Form8-K, current report
Filed with the SECJan 12, 2026, 7:00 AM ET
Accession number0001193125-26-009725

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.